戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1 sis due to troglitazone (a thiazolidinedione antidiabetic agent).
2 y mass index, use of insulin, and other oral antidiabetic agents).
3 ntroquinonol indicate that it is a potential antidiabetic agent.
4 ium, which is a proposed insulin mimetic and antidiabetic agent.
5 tential role for EGCG, or derivatives, as an antidiabetic agent.
6 nstrate the importance of IF1 as a potential antidiabetic agent.
7  which supports the role of camel milk as an antidiabetic agent.
8 sing candidate for further development as an antidiabetic agent.
9 hypoglycemia, and can be combined with other antidiabetic agents.
10 eed the in vitro activity of known synthetic antidiabetic agents.
11 ent, whereas 7 (28%) of 25 controls required antidiabetic agents.
12 receptor pharmacology that may lead to novel antidiabetic agents.
13 long-acting insulin analogues and noninsulin antidiabetic agents.
14 ery and design of GK activators as potential antidiabetic agents.
15 ctivators represent a potential new class of antidiabetic agents.
16 t passive GR antagonists may have utility as antidiabetic agents.
17 es-a group of potent PPAR gamma agonists and antidiabetic agents.
18 ailability of several unique classes of oral antidiabetic agents.
19  thiazolidinedione (TZD) and certain non-TZD antidiabetic agents.
20 lated compounds may represent a new class of antidiabetic agents.
21 R PAMs may become clinically useful as novel antidiabetic agents.
22   Such chemical entities may prove useful as antidiabetic agents.
23 th other forms of therapy, for example, oral antidiabetic agents.
24 nimal models and have promise as potent oral antidiabetic agents.
25 iet and exercise therapy and the use of oral antidiabetic agents.
26  using Click chemistry to identify potential antidiabetic agents.
27 metformin while remaining sensitive to other antidiabetic agents.
28 in different food formulations as functional antidiabetic agents.
29          The main outcome was the receipt of antidiabetic agents.
30       A significant reduction in use of oral antidiabetic agents (80%) and insulin (79%) followed sur
31                    Patients starting a third antidiabetic agent after receiving a metformin-containin
32 ssant, antihyperlipidemic, antiulcerant, and antidiabetic agents--also demonstrated significant price
33 e and significant increase in the receipt of antidiabetic agents among all people with diabetes durin
34 ile basal insulin remains the most effective antidiabetic agent and substantially reduces the risk of
35 lipid-lowering drugs, diabetes and/or use of antidiabetic agents, and hypertension and/or use of anti
36 g, and prostate cancer and use of TZD, other antidiabetic agents, and insulin were identified.
37      With few exceptions, the available oral antidiabetic agents are equally effective at lowering gl
38 azone and pioglitazone), a new class of oral antidiabetic agents, are "insulin sensitizers" and exert
39  binders, and thiazolidinediones, a class of antidiabetic agents, are particularly susceptible to thi
40 e, I discuss a rational basis for the use of antidiabetic agents as novel and potentially effective t
41 ngiotensin-converting enzyme inhibitor, oral antidiabetic agent, calcium, and vitamin D.
42 15d-PGJ2), or members of a new class of oral antidiabetic agents, e.g. BRL49653 and ciglitizone, has
43 t group) or short-acting insulin and/or oral antidiabetic agents for blood glucose >/=180-250 mg/dl (
44 idase-4 (DPP-4) inhibitors are commonly used antidiabetic agents for patients with advanced-stage chr
45 enosine, glucose-insulin-potassium, statins, antidiabetic agents, FX06, iron chelation, and ranolazin
46             Metformin, a commonly prescribed antidiabetic agent, has demonstrated antitumor activity
47 r-gamma (PPARgamma) agonists, a new class of antidiabetic agents, have been shown to possess antiinfl
48  peptidase-4 inhibitors (DPP-4is) as a third antidiabetic agent in patients with type 2 diabetes mell
49 .5-31.2 percentage points) in the receipt of antidiabetic agents in the adjusted model.
50         Metabolic stress, as well as several antidiabetic agents, increases hepatic nucleotide monoph
51 y of such vanadium coordination complexes as antidiabetic agents is described.
52 mediate-acting insulin analogues) with other antidiabetic agents is urgently required to guide approp
53                       PPARgamma agonists are antidiabetic agents known to suppress inflammatory macro
54 tion) in the presence of hyperglycemia, this antidiabetic agent may prove to have significant salutar
55  liver dysfunction is no longer valid; novel antidiabetic agents may provide adequate glucose control
56  some of the beneficial effects of PPARgamma antidiabetic agents may result, at least in part, from t
57                  Here, we show that both the antidiabetic agent metformin and insulin phosphorylate t
58             The complementary actions of the antidiabetic agents metformin hydrochloride and rosiglit
59                      TNFRI combined with the antidiabetic agent, metformin, improved DBD beyond that
60                    List prices of noninsulin antidiabetic agents (n = 10) increased by 165%, and net
61                           Troglitazone is an antidiabetic agent of the thiazolidinedione family.
62 ning the effects of intrauterine exposure to antidiabetic agents on longitudinal growth, and the impo
63 those who were not under treatment with oral antidiabetic agents or insulin.
64                     Compared with noninsulin antidiabetic agents, premixed insulin analogues were mor
65 ency in the thiazolidinedione (TZD) class of antidiabetic agents provided a dramatic increase in the
66                                          New antidiabetic agents show unexpected cardioprotective ben
67  that incorporate a structural moiety of the antidiabetic agent succinobucol.
68 T2D patients are routinely treated with oral antidiabetic agents such as sulfonylureas or dipeptidyl
69 ly, the same pathway is activated by certain antidiabetic agents such as thiazolidinediones.
70 lar target of the thiazolidinedione class of antidiabetic agents suggested a key role for PPAR-gamma
71                    Metformin is a first-line antidiabetic agent taken by 150 million people across th
72                                         Most antidiabetic agents target only 1 of several underlying
73        Thiazolidinediones are a new class of antidiabetic agent that improve insulin sensitivity and
74                 The effects of metformin, an antidiabetic agent that improves insulin sensitivity, on
75                           Troglitazone is an antidiabetic agent that improves the ability of adipocyt
76                       We describe a class of antidiabetic agents that act as nonessential, mixed-type
77 ones (TZDs) such as BRL 49653 are a class of antidiabetic agents that are agonists for the peroxisome
78 r 2 (SGLT-2) inhibitors are a novel class of antidiabetic agents that have been linked to an increase
79 ter 2 inhibitors (SGLT2i) were first used as antidiabetic agents that lower the blood glucose levels
80           Recent work has suggested that the antidiabetic agents, the thiazolidinediones (TZ), which
81 t, as well as members of a new class of oral antidiabetic agents, the thiazolidinediones, and a varie
82 s devoid of the side effects of the marketed antidiabetic agents thiazolidinediones and the dual agon
83  prostanoids and the synthetic high affinity antidiabetic agents thiazolidinediones.
84 Thus, PPARgamma activation in VSMCs, via the antidiabetic agent troglitazone or naturally occurring l
85 15-deoxy-delta12,14-prostaglandin J2 and the antidiabetic agent troglitazone.
86 r agonists to individuals treated with other antidiabetic agents using a Cox regression with inverse
87  and inhibition assays for canagliflozin, an antidiabetic agent verified its effective binding to bot
88 7, troglitazone, the first thiazolidinedione antidiabetic agent, was found to cause life-threatening
89                      To study a new class of antidiabetic agents, we compared two small, nonpeptide m
90                 In an effort to identify new antidiabetic agents, we have discovered a novel family o
91            Because PPARgamma is a target for antidiabetic agents, we investigated whether RXR ligands
92 ptidyl peptidase-4 inhibitor sitagliptin, an antidiabetic agent, which lowers blood glucose levels, a
93                    NAADP is thus a potential antidiabetic agent with therapeutic relevance.
94 nsulin sensitizers and incretin mimetics are antidiabetic agents with vastly different mechanisms of